Dr. Guido Magni is a Managing Director at Versant EuroVentures. He is on the Board of Directors at Gensight Biologics SA, AM-Pharma Holding BV, Anabasis SRL, Aprea Therapeutics AB, Nouscom AG, PIQUR Therapeutics AG, Tarveda Therapeutics, Inc. and AM-Pharma BV. Dr. Magni was previously employed as an Independent Director by Biotie Therapies Oyj, Managing Partner by Aravis AG, an Independent Director by Adolor Corp., and Global Head-Medical Science Division by Hoffmann-La Roche, Inc. He also served on the board at Mosaic Biomedicals SL and Synosia Therapeutics AG. He received his doctorate degree from The American University of Rome and a doctorate degree from the University of Padua.

Versant Ventures is a leading healthcare investment firm committed to helping exceptional entrepreneurs build the next generation of great healthcare companies. The firm invests across the healthcare sector and at all stages of company development, with an emphasis on the discovery and development of novel therapeutics. With $1.9 billion under management and offices in North America and Europe, Versant has built a team with deep investment, operating, and scientific expertise that enables a hands-on approach to company building. Since the firm’s founding in 1999, nearly 50 Versant companies have achieved successful acquisitions or IPOs.